Sign in
Taking peopleNo phase

Following adults with antiphospholipid syndrome over time

Follows adults with antiphospholipid syndrome to observe how their condition develops over time.

Key facts

Who runs it
University Hospital, Rouen
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Status
Recruiting
People taking part
200 people, planned
Started
16 Oct 2019
Expected to end
16 Oct 2032
Type of study
Observational
Treatments tested
  • Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with antiphospholipid syndrome, to follow them over time. This is a condition where the immune system makes antibodies that raise the risk of blood clots or pregnancy problems.

Age
Over 18 years and under 75 years.
Sex
All sexes can join.
Disease stage
Antiphospholipid syndrome that meets the 2006 Sydney classification.

Main reasons for not taking part

  • Age 75 or over
  • Syndrome that does not meet the 2006 Sydney classification

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Adult patients over 18 years of age and under 75 years of age
  • Antiphospholipid syndrome meeting the 2006 Sydney classification

Who cannot take part

  • Syndrome not meeting the 2006 Sydney classification
  • Patients under the age of 75 or over

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Antiphospholipid syndrome (APLS) is a rare pathology characterized by the association of thrombotic (arterial, venous) or obstetric clinical manifestations and the persistent presence at least twelve weeks apart of antiphospholipid antibodies (APL). It is also accompanied by accelerated atherosclerosis responsible for an increased incidence of myocardial infarction, peripheral arterial disease and stroke explaining the high cardiovascular morbidity and mortality of these patients. APS can be isolated (primary) or integrated into an autoimmune pathology such as systemic lupus erythematosus (SLE), thus defining secondary APS. Current treatment is based on anticoagulation. Currently, epidemiological data that have evaluated recurrences have estimated a rate of 5% per year. However, these studies are old and due to the significant heterogeneity of patients included in this registry, it seems that these figures are not in agreement with clinical reality.

Read full original descriptionShow less

Furthermore, several new therapeutic developments have emerged in the field of anticoagulation with the marketing of DOACs, making the EUROPHOSPHOLIPIDE data questionable. Currently, there are no clinical studies to justify the use of DOACs in this indication, but several patients have received these drugs due to intolerance or refusal of vitamin K antagonists. The other therapeutic innovation compared to the data from the EUROPHOSPHOLIPIDE cohort is the increasing use of hydroxychloroquine in clinical practice in patients with primary APS. A trial (APLAQUINE) is currently underway in our department which aims to study the endothelial protective effect of this treatment in patients with primary APS.

Treatments tested

  • Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Plain-language title
Following adults with antiphospholipid syndrome over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07178925, who can take part
Record updated
27 October 2026